In an editorial, one expert said the choice of DOAC in VTE is “no longer a toss-up,” with apixaban the clear winner.
A local doctor is hopeful a change in warnings on hormone replacement therapy for menopause will lead to more women exploring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results